Navigation Links
The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
Date:9/13/2007

PITTSBURGH, Sept. 13 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the private/public partnership putting the region's life sciences industry on a fast track for growth, announced that Peter M. DeComo, Chairman and Chief Executive Officer, Renal Solutions, Inc., John A. Kuzmishin, Vice President of Strategic Business Initiatives, UPMC, John L. Miclot, President and Chief Executive Officer, Respironics, and Elizabeth S. Woo, Ph. D., Vice President, Biotechnology, Thermo Fisher Scientific have been elected to the PLSG Board of Directors.

"We are extremely honored that Mr. DeComo, Mr. Kuzmishin, Mr. Miclot and Dr. Woo have agreed to join our board of directors. Their business experience with life science organizations, combined with their significant credentials and achievements, make them a tremendous asset to help guide the PLSG in our efforts to continue to drive innovation and commercialize more life sciences technologies in the region," said John W. Manzetti, PLSG's President and CEO.

About Peter M. DeComo

Mr. DeComo, is a co-founder of Renal Solutions, Inc. (RSI), an innovator in the development of renal dialysis systems for both the institutional and home environments. He serves as the company's Chairman and Chief Executive Officer. Before co-founding RSI, he was the Chief Operating Officer of HemoTherapies Inc., a start-up company in San Diego, commercializing the only FDA cleared Liver Dialysis System. He was previously Senior Vice President of the Specialty Pharmacy Division for Olsten Health Services, now Accredo, a $600 million specialty pharmacy provider. Prior to joining Olsten, Mr. DeComo held numerous senior level positions in the health care industry, launching and commercializing specialized products and services to patients in the home setting. He has served as a Director on the Board of Curative Health Services and is affiliated with a number of healthcare related organizations and advocacy groups. Mr. DeComo received his MS and BS degrees in Healthcare/Business Management from the University of Pittsburgh.

About John A. Kuzmishin

Mr. Kuzmishin is a senior member of the Strategic Business Initiatives group at the University of Pittsburgh Medical Center. His responsibilities include sourcing, structuring and overseeing direct investments as well as general business development for UPMC. Prior to joining UPMC in 2004, Mr. Kuzmishin spent 15 years as a healthcare investment banker, most recently as head of the healthcare investment banking group at Robert W. Baird & Co. (1996 - 2004). Prior to Baird he worked in the investment banking groups at Vector Securities International (1990 - 1996) and Shearson, Lehman Hutton Inc. (1988 - 1990). Mr. Kuzmishin graduated Phi Beta Kappa with honors from The College of Wooster in 1988 earning a Bachelor of Arts in Business Economics.

About John L. Miclot

John L. Miclot became President and CEO of Respironics, Inc., on December 1, 2003. In November 2002 he was appointed the company's Chief Strategic Officer responsible for developing and implementing strategic business and growth initiatives, both domestically and internationally, for each of Respironics' four divisions. In May 2003, he was elected to the Board of Directors. Prior to his position as Chief Strategic Officer he was the President of the Homecare Division from July 1999 to November 2002, where he oversaw strategic direction, sales and marketing, operations as well as research and development for the company's largest division. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies where he had served as Senior Vice President, Sales and Marketing from 1995-1998. He was appointed Group Vice President, Sleep Disorders, and was quickly promoted to Senior Vice President, Sales, Marketing and Manufacturing.

About Elizabeth S. Woo, Ph.D.

As Vice-President of Sales, Biotechnology Market & Application Specialists Program for Thermo Fisher Scientific, Dr. Woo is responsible for all aspects of sales to the biotechnology/ biopharmaceutical market segment, including sales expenditures, business development, P&L, pricing and financial modeling, contracting, forecasting and territory development. Prior to becoming Vice President, Dr. Woo held positions as Director of Marketing, Senior Director of Business Development, Senior Director of Technical Marketing and Product Manager. Dr. Woo is also an accomplished Bench Scientist. She possesses a Doctorate in Pharmacology from George Washington University Medical Center and a Bachelor of Science Degree in Biological Sciences from Carnegie Mellon University.

About the Pittsburgh Life Sciences Greenhouse (PLSG)

The PLSG invests in and supports the growth of biosciences companies in southwestern Pennsylvania. The PLSG has investment and business growth programs to increase the linkage between research, technology and commercialization; nurture and develop entrepreneurial biosciences enterprises; grow the region's talent pool in the life sciences; and help biosciences firms locate, expand or start-up in the Greater Pittsburgh region. http://www.plsg.com


'/>"/>
SOURCE The Pittsburgh Life Sciences Greenhouse
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):